SI9300591A - Water soluble camptothecin derivatives - Google Patents

Water soluble camptothecin derivatives Download PDF

Info

Publication number
SI9300591A
SI9300591A SI9300591A SI9300591A SI9300591A SI 9300591 A SI9300591 A SI 9300591A SI 9300591 A SI9300591 A SI 9300591A SI 9300591 A SI9300591 A SI 9300591A SI 9300591 A SI9300591 A SI 9300591A
Authority
SI
Slovenia
Prior art keywords
camptothecin
ethylenedioxy
compound
formula
methylenedioxy
Prior art date
Application number
SI9300591A
Other languages
English (en)
Slovenian (sl)
Inventor
Karen LACKEY
Michael Joseph Luzzio
Michael Glenn Evans
Jeffrey Mark Besterman
Daniel David Sternbach
Michael Robert Peel
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of SI9300591A publication Critical patent/SI9300591A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI9300591A 1992-11-12 1993-11-11 Water soluble camptothecin derivatives SI9300591A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97536392A 1992-11-12 1992-11-12
US97536492A 1992-11-12 1992-11-12

Publications (1)

Publication Number Publication Date
SI9300591A true SI9300591A (en) 1994-06-30

Family

ID=27130580

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300591A SI9300591A (en) 1992-11-12 1993-11-11 Water soluble camptothecin derivatives

Country Status (12)

Country Link
US (1) US6100273A (ja)
EP (1) EP0673380A1 (ja)
JP (1) JPH08503221A (ja)
CN (1) CN1091742A (ja)
AP (1) AP9300587A0 (ja)
AU (1) AU5604594A (ja)
CA (1) CA2148819A1 (ja)
IS (1) IS4092A (ja)
MX (1) MX9307011A (ja)
MY (1) MY109296A (ja)
SI (1) SI9300591A (ja)
WO (1) WO1994011377A2 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
IT1269862B (it) * 1994-05-30 1997-04-15 Indena Spa Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono
US5496952A (en) * 1995-02-07 1996-03-05 North Carolina State University Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
JPH08333370A (ja) * 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AU2001243515A1 (en) * 2000-03-08 2001-09-17 Rhode Island Hospital, A Lifespan Partner Combination drug therapy
US6825206B1 (en) * 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US6593334B1 (en) 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
US20080058411A1 (en) 2004-02-18 2008-03-06 Gpc Biotech Ag Methods For Treating Resistant Or Refractory Tumors
EP2027853A3 (en) 2004-06-18 2011-01-05 Agennix USA Inc. Kinase inhibitors for treating cancers
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
MX2010003881A (es) * 2007-10-09 2010-07-28 Univ Pennsylvania El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.
US8722886B1 (en) * 2012-11-13 2014-05-13 Bionumerik Pharmaceuticals, Inc. Methods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin
CA3045752A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
EP3725798A4 (en) * 2017-12-15 2021-11-10 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. BIOACTIVE CONJUGATE, METHOD FOR ITS MANUFACTURING AND USES
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
US20230158154A1 (en) * 2021-11-09 2023-05-25 Tubulis Gmbh Conjugates comprising a phosphorus (v) and a camptothecin moiety

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
HU213136B (en) * 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
ES2137932T3 (es) * 1990-09-28 2000-01-01 Smithkline Beecham Corp Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
US5126351A (en) * 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
DE69209969T2 (de) * 1991-10-29 1996-09-12 Glaxo Wellcome Inc Wasserlösliche Camptothecinderivate
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
CA2087898A1 (en) * 1992-01-24 1993-07-25 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.

Also Published As

Publication number Publication date
MY109296A (en) 1996-12-31
CA2148819A1 (en) 1994-05-26
WO1994011377A2 (en) 1994-05-26
AU5604594A (en) 1994-06-08
MX9307011A (es) 1994-05-31
JPH08503221A (ja) 1996-04-09
IS4092A (is) 1994-05-13
CN1091742A (zh) 1994-09-07
WO1994011377A3 (en) 1994-08-04
US6100273A (en) 2000-08-08
AP9300587A0 (en) 1995-05-05
EP0673380A1 (en) 1995-09-27

Similar Documents

Publication Publication Date Title
SI9300591A (en) Water soluble camptothecin derivatives
RU2119921C1 (ru) Производные камптотецина, способы их получения, соединения, фармацевтическая композиция
US5559235A (en) Water soluble camptothecin derivatives
US5342947A (en) Preparation of water soluble camptothecin derivatives
US5223506A (en) Cyclic antitumor compounds
US5126351A (en) Antitumor compounds
AU652728B2 (en) Camptothecin analogs as potent inhibitors of human colorectal cancer
EP0251361A1 (en) New di- and tetrahydroisoquinoline derivatives
AU638205B2 (en) Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases
WO1994025466A1 (en) Water soluble derivatives of camptothecin and their use as antitumor agents
SU795469A3 (ru) Способ получени производныхуРАцилА
PL165488B1 (pl) Sposób wytwarzania nowych 4 -[3-(4-oksotiazolidynylo)] butynylamin PL PL PL PL
SI9300183A (sl) Vodotopni kamptotecinski derivati
WO2023007181A1 (en) Phenothiazine antipsychotics for use in the treatment of glioblastoma
PL173684B1 (pl) Pochodne kamptotecyny i sposób wytwarzania pochodnych kamptofecyny
JPH05310761A (ja) 新規なｎ，ｎ−ビス−（２−クロロエチル）ホスホルジアミデート
GB2280674A (en) Pyrido[3,4-b]-pyridine antitumor compounds